

Simultaneous Free Flap Breast Reconstruction Combined with Contralateral Mastopexy or Breast Reduction: A Propensity Matched NSQIP Study on Postoperative Outcomes

Cindy Gombaut BS, Melanie Bakovic BS, Hoang-Viet Tran BS, Jennifer Goldman BA, Bharat Ranganath MD
The George Washington University School of Medicine and Health Sciences, Washington, D.C.

Introduction

Simultaneous free flap breast reconstruction combined with contralateral mastopexy or breast reduction can **increase patient satisfaction and minimize the need for a second procedure.**

Surgeon concerns of increases in operative time, postoperative complications, and final breast symmetry may decrease likelihood of these procedures being done concurrently.

Purpose

Analyze postoperative outcomes of simultaneous contralateral mastopexy or breast reduction with free flap breast reconstruction.

Methods

- ACS-NSQIP database from 2010-2020
- Two patient cohorts:
- Free flap breast reconstruction only
- Free flap breast reconstruction combined with contralateral mastopexy or breast reduction
- Perioperative variables assessed included demographic data, comorbidities, and perioperative data.
- Using a neighbor matching algorithm, we performed a 1:1
 propensity score matching of 602 free flap breast
 reconstruction patients and 621 with concurrent
 contralateral operation patients.
- Bivariate analysis for postoperative surgical and medical complications was performed for outcomes in the propensity-matched cohort.

Results

- 11,308 cases who underwent microsurgical free flap breast reconstruction from the ACS-NSQIP database from the beginning of 2010 to the end of 2020.
- A total of 621 patients underwent a simultaneous contralateral mastopexy or breast reduction.
- After propensity-score matching, there were **no significant differences** in patient characteristics, perioperative variables, or postoperative medical complications between the two cohorts.

Table 1. Multivariate regression analysis of unmatched variables associated with concurrent mastopexy or breast reduction.

| Variable | | Odds ratio | 95% CI | P value |
|-----------------------------------|------------------------------|------------|-------------|---------|
| | | Exp(B) | Lower-Upper | |
| Age | | 1.032 | 1.022-1.042 | <.001 |
| Year of Oper | | 0.953 | 0.924-0.983 | .002 |
| Race | White | | | <.001 |
| | Asian | 0.457 | 0.200-1.043 | 0.063 |
| | Black or African American | 1.349 | 1.009-1.804 | 0.043 |
| | Hispanic | 1.928 | 1.390-2.674 | <.001 |
| | Other | 2.671 | 0.805-8.857 | 0.108 |
| | Unknown | 4.279 | 3.513-5.211 | <.001 |
| BMI | | 1.045 | 1.015-1.077 | 0.004 |
| WHO | non-obese | | | 0.532 |
| | Class I | 0.986 | 0.753-1.291 | 0.918 |
| | Class II | 0.811 | 0.507-1.297 | 0.382 |
| Outpatient | | 1.889 | 1.362-2.622 | <.001 |
| Smoker | | 0.662 | 0.438-1.002 | 0.051 |
| Diabetes | None | | | 0.114 |
| | Insulin | 0.475 | 0.188-1.197 | 0.114 |
| | Non-insulin | 0.743 | 0.496-1.112 | 0.149 |
| Steroid use for chronic condition | | 1.433 | 0.722-2.845 | 0.304 |
| COPD | | 0.814 | 0.188-3.535 | 0.784 |
| Hypertension | | 1.231 | 0.997-1.520 | 0.054 |
| CHF | | 0.000 | 0.000 | 0.999 |
| Specialty | Plastics | | | 0.990 |
| | General | 0.965 | 0.586-1.591 | 0.889 |
| | Other | 0.000 | 0.000 | 0.998 |
| ASA Class | I | | | 0.470 |
| | II | 0.729 | 0.483-1.100 | 0.132 |
| | III | 0.732 | 0.479-1.119 | 0.150 |
| | IV | 0.542 | 0.145-2.025 | 0.362 |
| Wound Classification | Clean | | | 0.908 |
| | Clean/ Contaminated | 1.203 | 0.695-2.082 | 0.508 |
| | Contaminated | 0.000 | 0.000 | 0.997 |
| | Dirty/Infected | 0.708 | 0.089-5.613 | 0.743 |
| Low Serum Albumin | | 1.022 | 0.851-1.227 | 0.819 |
| Total operative time | | 0.997 | 0.996-0.997 | <.001 |
| Length of total hospital stay | | 0.998 | 0.978-1.018 | 0.846 |

Table 3. Bivariate analysis of propensity score-matched 30 day postoperative complications.

| | Free Flap Only (602) | Simultaneous Procedure (621) | P-value |
|--------------------------------------|----------------------|---------------------------------|---------|
| Wound, n (%) | | | |
| Superficial SSI | 27 (4.5%) | 34 (5.5%) | 0.427 |
| Deep Incisional SSI | 8 (1.3%) | 7 (1.1%) | 0.749 |
| Organ Space SSI | 2 (0.3%) | 3 (0.5%) | 1.000 |
| Wound dehiscence | 8 (1.3%) | 5 (0.8%) | 0.372 |
| Respiratory, n (%) | | | |
| Pneumonia | 2 (0.3%) | 3 (0.5%) | 1.000 |
| Pulmonary embolism | 4 (0.7%) | 3 (0.5%) | 0.722 |
| Intubation | 1 (0.2%) | - | 0.492 |
| Failure to wean | 1 (0.2%) | - | 0.492 |
| Renal, n (%) | | | |
| Renal insufficiency | _ | - | |
| Acute renal failure | _ | - | |
| UTI | 4 (0.7%) | 5 (0.8%) | 1.000 |
| Cardiovascular, n (%) | | | |
| CVA/Stroke with neurological deficit | - | - | |
| Myocardial infarction | 1 (0.2%) | 2 (0.3%) | 0.582 |
| DVT requiring therapy | 3 (0.5%) | 4 (0.6%) | 1.000 |
| Cardiac arrest | _ | - | |
| Transfusion | 42 (7%) | 34 (5.5%) | 0.277 |
| Sepsis, n (%) | 3 (0.5%) | 4 (0.6%) | 1.000 |
| Septic shock, n (%) | _ | 1 (0.2%) | 1.000 |
| Return to OR, n (%) | 64 (10.6%) | 56 (9.0%) | 0.343 |
| Unplanned readmission, n (%) | _ | 2 (0.3%) | 0.372 |
| Reoperation within 30 days, n (%) | 2 (0.4%) | 3 (0.7%) | 0.913 |

Key Points

- Simultaneous free flap breast reconstruction combined with contralateral mastopexy or breast reduction can be performed safely and effective without an increase in postoperative complication rates.
- This can improve surgeon competence in offering this combination of procedures as an option to breast cancer survivors, leading to better patient outcomes in terms of symmetrical and aesthetically pleasing results, reduced costs, and elimination of the need for a second operation.